March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
Nature23y
Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling
Figure 4: Impaired antigen receptor–activated B cell proliferation and humoral responses ... (FITC)-labeled mAbs to B220, CD4, CD5 or IgD (PharMingen, San Diego, CA), phycoerythrin (PE)-labeled ...
Targeted Oncology6d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
Pharmabiz5d
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Beyond MB-105, March Bio is advancing a robust pipeline of cell therapies to further expand its potential to improve treatment options for difficult diseases and malignancies. MB-105 is a ...
Morningstar7d
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
MB-105 is a first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia ...